Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.

ABSTRACT:

Background

In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics which prohibit clinical response to anti-HER2 therapies and drive disease progression are not yet fully known. Integrative whole-genome and transcriptomic sequencing data from both primary and metastatic HER2-positive breast cancer will enhance our understanding of underlying biological processes.

Methods

Here, we used WGS and RNA sequencing data of 700 metastatic breast tumors, of which 68 being HER2+, to search for specific genomic features of HER2+ disease and therapy resistance. Furthermore, we integrated results with transcriptomic data to associate tumors exhibiting a HER2+-specific gene expression profile with ERBB2 mutati

SUBMITTER: Verschoor N 

PROVIDER: S-EPMC10648326 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature